2017 Fiscal Year Final Research Report
The Mechanism of Gemcitabine and Cisplatin resistance in bladder cancer cells.
| Project/Area Number |
16K20148
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SUZUKI Hiromu 札幌医科大学, 医学部・分子生物学講座, 教授 (20381254)
MASUMORI Naoya 札幌医科大学, 医学部・泌尿器科学講座, 教授 (20295356)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | 膀胱癌 / マイクロRNA / 抗がん剤抵抗性 |
|---|
| Outline of Final Research Achievements |
In present study, we aimed to unveil the mechanism of CDDP resistance in bladder cancer cells and focused on microRNA-200b. We established CDDP resistant T24 bladder cancer cells (T24RC) and compared to parental cells (T24). Among these two cell lines many microRNAs were changed dramatically. Over expression of microRNA200b, re-sensitize T24RC cells to CDDP. Moreover we confirmed that microRNA-200b is epigenetically regulated. When treated by 5-aza-2'-deoxycitidine, expression of microRNA-200b recovered and also sensitivity to CDDP recovered. Combination of CDDP and 5-aza-2'-deoxycytidine synergistically suppressed cell proliferation in T24RC cells.
|
| Free Research Field |
尿路上皮癌
|
